AXA reduced its position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 13.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,635 shares of the biopharmaceutical company’s stock after selling 15,821 shares during the period. AXA owned 0.33% of Loxo Oncology worth $8,994,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the business. Lord Abbett & CO. LLC grew its position in shares of Loxo Oncology by 372.0% in the second quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after purchasing an additional 582,862 shares in the last quarter. FMR LLC grew its position in shares of Loxo Oncology by 12.1% in the second quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock valued at $352,420,000 after purchasing an additional 472,814 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Loxo Oncology by 50.2% in the second quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock valued at $75,121,000 after purchasing an additional 312,988 shares in the last quarter. BlackRock Inc. lifted its holdings in Loxo Oncology by 20.6% in the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after acquiring an additional 273,291 shares during the last quarter. Finally, Voya Investment Management LLC lifted its holdings in Loxo Oncology by 3,757.2% in the second quarter. Voya Investment Management LLC now owns 236,177 shares of the biopharmaceutical company’s stock valued at $18,939,000 after acquiring an additional 230,054 shares during the last quarter. Institutional investors own 99.98% of the company’s stock.
In related news, Director Avi Z. Naider sold 5,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $90.00, for a total value of $450,000.00. Following the completion of the sale, the director now owns 144,118 shares in the company, valued at $12,970,620. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $86.52, for a total transaction of $133,327.32. Following the sale, the insider now owns 1,541 shares of the company’s stock, valued at $133,327.32. The disclosure for this sale can be found here. Insiders have sold 1,614,555 shares of company stock valued at $124,567,942 in the last quarter. Insiders own 44.40% of the company’s stock.
Shares of Loxo Oncology, Inc. (NASDAQ LOXO) traded up $1.13 on Friday, hitting $89.99. 440,691 shares of the stock traded hands, compared to its average volume of 334,044. Loxo Oncology, Inc. has a twelve month low of $36.75 and a twelve month high of $95.92. The firm has a market capitalization of $2,660.25, a P/E ratio of -15.44 and a beta of 2.54.
A number of research analysts have commented on the company. Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday. BTIG Research restated a “buy” rating and set a $102.00 price target (up from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Cowen reaffirmed a “buy” rating on shares of Loxo Oncology in a research report on Thursday, September 28th. BidaskClub raised Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Citigroup reissued a “buy” rating and issued a $112.00 target price (up previously from $86.00) on shares of Loxo Oncology in a report on Friday, October 20th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $90.57.
COPYRIGHT VIOLATION NOTICE: “Axa Trims Stake in Loxo Oncology, Inc. (LOXO)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/loxo-oncology-inc-loxo-shares-sold-by-axa.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.